Could your own tumor cells fight cancer? new trial tests immune cell therapy
NCT ID NCT03449108
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a treatment called LN-145, made from a patient's own immune cells taken from their tumor. These cells are grown in a lab and then given back to the patient to attack the cancer. The study includes people with ovarian cancer, triple-negative breast cancer, anaplastic thyroid cancer, and bone or soft tissue sarcomas that have not responded to other treatments. The goal is to see if this approach can shrink tumors and control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tumor-infiltrating lymphocytes (LN-145 or LN-145-S1) plus aldesleukin and chemotherapy
- What this could lead to
- If successful, this could offer a new treatment option for patients with hard-to-treat cancers like ovarian, triple-negative breast, and bone sarcomas.
- What could go wrong
- This is an early-phase trial with only 30 participants, so results may not apply broadly. Side effects from the cell therapy and chemotherapy can be severe.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BONE SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive antibody light up hidden tumors?
- Can a High-Fiber diet shield the gut during breast cancer therapy?
- Can a new PET tracer reveal hidden immune clues in tumors?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can a Two-Drug combo tame a rare and aggressive gynecologic cancer?
- Can mapping tumor DNA unlock personalized breast cancer care?